Gastroenterology and Hepatology Unit, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Best Pract Res Clin Gastroenterol. 2019 Jun-Aug;40-41:101636. doi: 10.1016/j.bpg.2019.101636. Epub 2019 Jul 20.
The number of disorders now linked to increased intestinal mucosal permeability implies that a substantial percent of the population is affected. Drug interventions targeting reduced tight junctional permeability are being pursued. Although hyper-permeability in itself is not a clinically recognized disease entity, its relationship to disease processes has driven interest in measuring, and even monitoring mucosal permeability in vivo. Along with improved knowledge of gut barrier physiology, advances have been made in tests and biomarkers of barrier function. Drawing from our experiences in the past decade, considerations and challenges faced in assessing in vivo intestinal permeability are discussed herein, along with indications of what the future might hold.
现在，与肠道黏膜通透性增加相关的疾病数量表明，相当一部分人口受到了影响。目前正在进行针对减少紧密连接通透性的药物干预。虽然通透性本身不是一种临床上公认的疾病实体，但它与疾病过程的关系促使人们对测量甚至监测体内黏膜通透性产生了兴趣。随着对肠道屏障生理学的认识不断提高，屏障功能的测试和生物标志物也取得了进展。本文借鉴了我们过去十年的经验，讨论了评估体内肠道通透性所面临的考虑因素和挑战，并展望了未来可能的发展方向。
